OR WAIT null SECS
The companies have agreed to an all-stock merger of equals transaction anticipated to close in the second half of 2016.
On May 3, 2016, IMS Health Holdings, a global healthcare information and technology services company, and Quintiles Transnational Holdings Inc., a pharmaceutical contract research organization (CRO), announced their plans to combine in an all-stock merger of equals transaction. The merged company will be called Quintiles IMS Holdings, Inc., the companies said in a press announcement.
Based on the closing of IMS Health and Quintiles common stock prices on May 2, 2016, the equity market capitalization of the joined companies is more than $17.6 billion and the enterprise value is more than $23 billion. Under the terms of the merger agreement, IMS Health shareholders will receive a fixed exchange ratio of 0.384 shares of Quintiles common stock for each share of IMS Health common stock.
Upon completion of the merger, IMS Health shareholders will own approximately 51.4% of the shares of the combined company on a fully diluted basis, and Quintiles shareholders will own approximately 48.6% of the combined company on a fully diluted basis. The transaction is subject to customary closing conditions, including regulatory approvals and approval by both IMS Health and Quintiles shareholders and is expected to close in the second half of 2016.
Source: IMS Health